Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Q Biomed Inc (QBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 29,684
  • Shares Outstanding, K 14,466
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,270 K
  • 60-Month Beta 5.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/15/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 02/28/19
See More
  • Average Estimate -0.14
  • Number of Estimates 1
  • High Estimate -0.14
  • Low Estimate -0.14
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +17.65%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6000 +28.25%
on 03/07/19
2.3700 -13.42%
on 03/13/19
+0.1370 (+7.15%)
since 02/19/19
3-Month
0.9000 +128.00%
on 12/31/18
2.5400 -19.21%
on 01/25/19
+0.6720 (+48.70%)
since 12/19/18
52-Week
0.9000 +128.00%
on 12/31/18
3.9500 -48.05%
on 04/05/18
-0.9820 (-32.37%)
since 03/19/18

Most Recent Stories

More News
OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today unveiled the list of OTCQX® Best Market and OTCQB® Venture Market company presentations...

EVLLF : 0.6711 (+29.06%)
TRLFF : 0.4000 (+0.13%)
AITB : 4.6000 (-2.65%)
BICXD : 4.5400 (-9.02%)
MMNFF : 3.0200 (-1.95%)
ATEA : 5.7200 (-4.51%)
CWBHF : 18.4100 (+9.26%)
CVSI : 5.0200 (+6.58%)
DUOT : 0.6800 (unch)
CRLBF : 9.2000 (-1.08%)
ARREF : 0.8200 (unch)
CLOK : 0.9900 (+10.00%)
MLCPF : 2.5500 (-2.30%)
CNBX : 0.3841 (-2.76%)
HEOFF : 0.6188 (-4.74%)
MJARF : 2.9100 (-3.64%)
ALEAF : 1.8000 (+5.26%)
OTCM : 35.0000 (+3.35%)
NUPMF : 1.7800 (+2.30%)
GLDLF : 0.7695 (+1.38%)
NMUS : 0.6967 (+35.54%)
NLST : 0.5295 (-2.67%)
GBPT : 0.2600 (-48.00%)
IMLFF : 0.4454 (-2.11%)
KSHB : 5.6300 (-0.27%)
CORVF : 1.6500 (-1.78%)
ELLXF : 2.6600 (+4.70%)
RSSS : 2.2400 (+12.00%)
ISYRF : 1.1000 (-8.33%)
FLUX : 1.3800 (-1.43%)
NWGI : 0.3750 (-6.25%)
QBIO : 2.0520 (+4.69%)
WIZD : 0.1150 (-8.00%)
MRMD : 3.3850 (-5.97%)
GRWG : 3.0800 (-4.35%)
BRTI : 0.2412 (+0.50%)
GTBP : 0.3875 (-3.13%)
MRIC : 3.1000 (-1.59%)
DYAI : 3.1000 (+5.80%)
GTBIF : 14.0100 (+0.69%)
MTAFF : 0.9430 (+3.63%)
EMHTF : 3.4600 (+12.23%)
ITHUF : 5.5400 (-2.81%)
ALYE : 2.5000 (-16.67%)
VTLR : 0.1806 (-7.24%)
ARHH : 1.9600 (+0.51%)
OWCP : 0.0396 (+0.25%)
STLHF : 0.7180 (+0.35%)
PPCB : 0.0119 (-0.83%)
ARTH : 0.3900 (+2.63%)
ACRGF : 19.8600 (-6.54%)
Q Biomed's Set to Transform Multi-Billion Dollar Glaucoma Market

Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Company Spotlight article on high profile biomedical...

QBIO : 2.0520 (+4.69%)
Demand for New Glaucoma Therapies Has Greatest Potential to Drive Value for Q BioMed's Shareholders

NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (OTCQB: QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally....

QBIO : 2.0520 (+4.69%)
Q BioMed Responds to OTC Markets Request for Clarity on Investor Awareness Activity

Q BioMed Inc. (OTCQB: QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company.

QBIO : 2.0520 (+4.69%)
Biotech Companies Introduce New Treatments as Concern Over Cancer Rises

Cancer is among one of the leading causes of death around the globe; namely, in 2018, there were a total estimated 18.1 million new cases worldwide. The International Agency for Research on Cancer (IARC)...

QBIO : 2.0520 (+4.69%)
CELG : 89.07 (+1.23%)
INCY : 85.67 (+0.06%)
SGEN : 72.86 (-0.80%)
CELGZ : 1.18 (+2.61%)
NKTR : 34.41 (-1.49%)
Biotechnology Companies See Growth in Optic Treatment Sectors

The vast number of people in need of medical treatment has grown tremendously over the years. Some cases are a result of environmental changes, yet others can be caused by genetics. Regardless, there is...

QBIO : 2.0520 (+4.69%)
AERI : 45.64 (-3.08%)
NVS : 92.99 (-0.19%)
VSTM : 3.41 (+0.89%)
AXSM : 12.95 (+12.90%)
FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (OTCQB: QBIO) Chairman and CEO, Denis...

QBIO : 2.0520 (+4.69%)
TPIV : 8.34 (+0.60%)
FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

NEW YORK , Feb. 5, 2019 /PRNewswire/ --  www.FinancialBuzz.com , a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with...

QBIO : 2.0520 (+4.69%)
FinancialBuzz.com Exclusive Interview With Chairman and CEO Denis Corin of Q BioMed Inc. Live From Times Square in New York City

www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (OTCQB: QBIO) Chairman and CEO, Denis...

QBIO : 2.0520 (+4.69%)
TPIV : 8.34 (+0.60%)
Q BioMed Seeks Multi-billion Dollar Opportunity with New Glaucoma Treatment Candidate

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / Shares of Q BioMed Inc. (OTCQB: QBIO) rose on heavy volume after the company announced that a new collaboration among researchers at McMaster University,...

QBIO : 2.0520 (+4.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade QBIO with:

Key Turning Points

2nd Resistance Point 2.1373
1st Resistance Point 2.0947
Last Price 2.0520
1st Support Level 1.9697
2nd Support Level 1.8873

See More

52-Week High 3.9500
Fibonacci 61.8% 2.7849
Fibonacci 50% 2.4250
Fibonacci 38.2% 2.0651
Last Price 2.0520
52-Week Low 0.9000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar